# Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1

> **NCT04748705** · PHASE2 · COMPLETED · sponsor: **Virios Therapeutics, Inc.** · enrollment: 422 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** IMC-1
- **DRUG:** Placebo BID Tablet

## Key facts

- **NCT ID:** NCT04748705
- **Lead sponsor:** Virios Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-03
- **Primary completion:** 2022-08-05
- **Final completion:** 2022-08-05
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04748705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04748705, "Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04748705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*